These results indicate that Artemether could be a new AMPK/GSK3β(ser9)/Nrf2 activator for the treatment of inflammation and oxidative stress and a potential therapeutic agent for Alzheimer's disease. This evidence concerns the gene PRKAA2 and early-onset autosomal dominant Alzheimer disease.